Related Experiment Videos
A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma
Ji Eun Uhm1, Kyoung Ha Kim, Seong Yoon Yi
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Leukemia & Lymphoma
|June 27, 2009
Summary
Higher doses of methotrexate (MTX) in treating primary central nervous system lymphoma may lead to better early response rates. This retrospective study compared two MTX regimens, finding improved complete response rates with the higher dose, despite similar overall survival outcomes.
Area of Science:
- Neuro-oncology
- Medical treatment efficacy
- Pharmacological dosing
Background:
- Primary central nervous system lymphoma (PCNSL) is a rare and aggressive brain tumor.
- Methotrexate (MTX) is a cornerstone chemotherapy agent for PCNSL.
- Optimal dosing strategies for high-dose MTX (HD-MTX) in PCNSL require further investigation.
Purpose of the Study:
- To compare the treatment outcomes of two different doses of intravenous methotrexate (MTX) in patients with newly diagnosed PCNSL.
- To evaluate the impact of HD-MTX dose escalation on response rates, survival, and early toxicity.
- To determine if a higher dose of MTX is associated with improved treatment efficacy in PCNSL.
Main Methods:
- Retrospective analysis of 72 patients with newly diagnosed PCNSL treated between 1995 and 2006.
- Comparison of two cohorts: Cohort 1 received 1 g/m(2) HD-MTX (n=36), and Cohort 2 received 3.5 g/m(2) HD-MTX (n=36).
- Evaluation of overall survival (OS), progression-free survival (PFS), complete response (CR)/unconfirmed complete response (CRu) rates, and early mortality.
Main Results:
- While OS and PFS were not statistically different between the 1 g/m(2) and 3.5 g/m(2) HD-MTX cohorts, Cohort 2 demonstrated significantly higher CR/CRu rates (52.8% vs. 16.7%, p=0.005).
- Cohort 2 experienced no deaths within 6 months of MTX therapy, contrasting with eight deaths in Cohort 1 (p=0.003).
- Despite similar outcomes after subsequent therapies, the higher early response rate in Cohort 2 suggests potential benefits of escalated HD-MTX dosing.
Conclusions:
- Higher dose intravenous methotrexate (3.5 g/m(2)) may improve early response rates in primary central nervous system lymphoma.
- While not impacting long-term survival in this study, escalated MTX dosing showed a trend towards reduced early mortality.
- Further prospective studies are warranted to confirm the benefits of high-dose MTX in PCNSL treatment.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...